+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 40 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are assessing the long-term safety of subcutaneous guselkumab in children with moderate to severe ulcerative colitis, Crohns disease, or juvenile psoriatic arthritis. This Phase 3, open-label study enrolls pediatric participants who previously received guselkumab in one of three primary studies and are considered by their investigator to benefit from continued treatment. The study aims to monitor safety over an extended period to better understand the effects of ongoing guselkumab use in these conditions. Participants who completed dosing in the primary studies will continue guselkumab treatment in this long-term extension study. Dosing schedules include injections every 8 weeks or every 4 weeks, depending on their original study arm and clinical status. Some participants may switch dosing intervals once during the study before unblinding, while others will maintain their initial regimen. The study allows continued access to guselkumab over the long term, with dosing adjustments guided by prior treatment plans and investigator discretion. Throughout the study, participants will be closely monitored for treatment-emergent adverse events for up to 6 years and 9 months. Assessments will include regular evaluations by investigators to ensure safety and adherence. Parents or legal representatives consent for children to participate, with assent obtained from capable participants aged 7 years and older. The study emphasizes long-term safety tracking and maintaining participant well-being during extended guselkumab therapy.

Age: 3Years +All GendersPhase 3
53 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.

Age: 18Years - 100YearsAll GendersPhase 3
161 locations
A

Actively Recruiting

Researchers are evaluating DB-OTO, an investigational gene therapy, for children, infants, adolescents, and adults who have severe to profound hearing loss caused by mutations in the otoferlin gene. This study aims to learn about the safety of DB-OTO, how well it is tolerated without ongoing discomfort, and how effective it is in improving hearing abilities. Participants will receive DB-OTO through one of several dosing approaches including unilateral intracochlear injection, bilateral intracochlear injection based on safety and efficacy data from an initial phase, or either unilateral or bilateral dosing. The trial is open-label and includes sequential cohorts to evaluate safety, tolerability, and efficacy. The study consists of different parts where dosing and monitoring are tailored accordingly. During the study, participants will undergo various assessments to measure hearing sensitivity using Pure Tone Audiometry and Auditory Brainstem Response tests, as well as speech perception and auditory skill evaluations. Safety will be monitored by tracking treatment-emergent adverse events up to week 104. Participants and their guardians will be closely followed for over two years to evaluate hearing improvements and any changes in speech abilities or safety outcomes.

All AgesAll GendersPhase 1Phase 2
17 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma who have received multiple prior treatments. This Phase 2 study focuses on determining the recommended doses and assessing the treatment in different participant groups based on previous therapies received. The study is sponsored by Janssen Research & Development, LLC and aims to provide new treatment options for this condition. Participants are divided into five cohorts based on their treatment history, including exposure to T cell redirection therapies and prior medications. Talquetamab is administered subcutaneously at recommended Phase 2 doses, with dosing schedules including biweekly administration in some cohorts. All participants will transition to an open-label extension phase to continue receiving the study treatment, followed by a long-term extension phase upon sponsor approval. Throughout the study, participants will undergo regular assessments to measure treatment response, safety, and tolerability. These include evaluations of overall response rate, duration of response, progression-free survival, quality of life questionnaires, laboratory tests, and monitoring for adverse events. The study duration includes follow-up to approximately 2 years and 10 months. Talquetamab concentrations and antibody presence will also be monitored to understand treatment effects and immune response.

Age: 18Years +All GendersPhase 2
78 locations
P

Actively Recruiting

Researchers are investigating TRK-950 in patients with advanced solid tumors and melanoma in an open-label phase III study. The study aims to assess the safety and tolerability of TRK-950 alone or in combination with nivolumab in patients with advanced solid tumors, and to evaluate the efficacy of TRK-950 in patients with advanced or recurrent unresectable melanoma who have previously received chemotherapy with dacarbazine and have no standard treatment options. The study includes three parts Part 1 administers two dose levels of TRK-950 to patients with advanced solid tumors refractory or intolerant to standard therapies Part 2 gives two dose levels of TRK-950 combined with nivolumab, with nivolumab dosed at 240 mg intravenously every two weeks Part 3 treats melanoma patients with one dose level of TRK-950. TRK-950 is given intravenously on days 1, 8, 15, and 22 of a 28-day cycle in most parts, with variations in dosing schedules depending on the part and combination with nivolumab. Participants will receive intravenous infusions of study drugs according to their assigned part and dose level. Researchers will monitor safety through dose-limiting toxicities, adverse events, and serious adverse events for up to one year. Pharmacokinetic profiles and antibody development against TRK-950 will be assessed. In Part 3, efficacy will be measured by response rates and survival outcomes over approximately 12 months. The study duration spans from initial dosing through follow-up assessments up to study completion in March 2028.

Age: 18Years +All GendersPhase 1Phase 2
10 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.

Age: 18Years +All GendersPhase 3
165 locations
C

Actively Recruiting

Researchers are studying an experimental drug called linvoseltamab compared to another drug, daratumumab, in adults with Smoldering Multiple Myeloma SMM who have a high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the progression to multiple myeloma better than daratumumab. The study also looks at side effects, drug levels in the blood, and whether the body makes antibodies against the study drug. Participants are randomly assigned to receive either linvoseltamab or daratumumab, both administered according to the study protocol. The trial follows participants for up to five years to assess clinical and biochemical progression-free survival and other outcomes. Additional measures include response rates, adverse events, quality of life, and antibody presence against linvoseltamab. During the study, participants will undergo regular evaluations including clinical assessments and laboratory tests to monitor disease status, drug levels, and side effects. Quality of life questionnaires and other patient-reported outcomes will be collected over several years. Safety and response will be closely monitored throughout the trial, which may last up to nine years in total for long-term outcomes.

Age: 18Years +All GendersPhase 3
33 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
56 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations

1-10 of 40

1